Study Details
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients with Advanced Solid Tumors
This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
2215-CL-0105
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
N/A
Condition
Advanced/Metastatic Cancer, Other
Phase
These clinical trials are usually the first time an experimental treatment is studied in a small group of people.
Phase 1
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Mar 2016 - Jun 2017
Masking
None (Open Label)
Enrollment number
6
A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients with Advanced Solid Tumors
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients with Advanced Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site US10001
Cleveland, United States, 44195